Business Context and Reporting Period
This Form 8-K Current Report was filed by Novavax, Inc. on October 2, 2008. The filing discloses the execution of new employment agreements and amendments for three senior officers: Penny Heaton, M.D. (Vice President, Development and Chief Medical Officer), Len Stigliano (Vice President, Chief Financial Officer, and Treasurer), and Raymond Hage (Senior Vice President of Commercial Operations).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Penny Heaton: Annual base salary of $292,905; target performance bonus of 40% of base salary.
- Len Stigliano: Annual base salary of $259,305; target performance bonus of 40% of base salary; reimbursement up to $25,000 for transportation and lodging expenses plus associated taxes.
- Raymond Hage: Employment term extended by one year; specific compensation figures not detailed in the summary text.
Material Changes Versus Prior Period
The filing details the following changes to executive arrangements effective October 2, 2008:
- New Agreement (Heaton): Established a new employment contract with a term ending October 1, 2009, including a 12-month non-compete clause and severance equal to 12 months of salary upon termination without cause or for good reason.
- Amended Agreement (Stigliano): Restated the July 2, 2007 agreement, extending the term to July 1, 2009. Added a specific reimbursement provision for commute expenses and set severance at 6 months of salary for termination without cause or for good reason. Includes a 6-month non-compete clause.
- Amendment (Hage): Extended the employment term of the August 2, 2007 agreement to September 1, 2009.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. The primary contingencies noted are the severance obligations triggered by termination without cause or for good reason for Dr. Heaton and Mr. Stigliano. Both executives are subject to confidentiality and non-competition provisions.
Key Facts for Investor Verification
- Verify the total cash and equity compensation impact of the new agreements on the company's operating expenses.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific performance goals tied to the 40% target bonuses.
- Assess the potential liability for severance payments ($292,905 for Dr. Heaton and $259,305 for Mr. Stigliano) in the event of executive turnover.
- Confirm the tax implications of the $25,000 commute reimbursement provided to Mr. Stigliano.